Clinical trials: Oral Cavity Disease
Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
This is a phase II randomized, open label study of durvalumab with/ without tremelimumab as neoadjuvant therapy and durvalumab maintenance after SoC RTx with/without cisplatin as post-surgical adjuvant therapy in treatment naïve…
- Conditions
- Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx, Oropharynx, Larynx
- Trial name
- NCT03737968
- Testing
- Durvalumab, durvalumab + tremelimumab
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV
Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN
This multicentre, randomised Phase II Pilot Study evaluates the efficacy of docetaxel, cisplatin and 5-fluorouracil or Cetuximab, followed by Cetuximab with radiotherapy.
- Conditions
- Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Squamous Cell Carcinoma of the Larynx Stage III, Squamous Cell Carcinoma of the Larynx Stage IV
- Trial name
- HNO-2 (NCT01884259)
- Testing
- Docetaxel, Cisplatin, 5-fluorouracil
- Where
- 8 sites in Austria
- Volunteers
- 100 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Oral Cavity Disease
Microneedle Pretreatment as a Strategy to Improve the Effectiveness of Topical Anesthetics Formulations
A randomized, crossover, double-blind, two-sessions clinical trial with 30 male volunteers was performed to access pain of local anesthesia after using a topical anesthetic associated or not with prior application of microneedles…
- Trial name
- NCT05267938
- Testing
- Topical Anesthetic, Local anesthetic
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Campinas, Brazil
Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV
Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck
Prevention of critical weight loss. In patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) weight loss is a relevant clinical problem during radiotherapy and might result in higher treatment related toxicity and…
- Conditions
- Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Laryngeal Squamous Cell Carcinoma Stage III, Laryngeal Squamous Cell Carcinoma Stage IV
- Trial name
- AGMT_HNO_PN (NCT02236936)
- Testing
- Standard care of parenteral nutrition, Parenteral over night nutrition, Cetuximab
- Where
- 7 sites in Austria
- Volunteers
- 8 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Oral Cavity Disease
Pain and Safety of Microneedles in Oral Cavity
A randomized, crossover, double-blind, placebo-controlled, one-session clinical trial with 30 male volunteers was performed to access pain and safety of microneedle topical application in different regions of the oral cavity.
- Trial name
- NCT03855397
- Testing
- Microneedle, Hypodermic needle, Flat patch
- Where
- Brazil
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Campinas, Brazil
Human Papillomavirus (HPV), Positive or Negative Head and Neck Squamous Cell Carcinoma (HNSCC) of the Hypopharynx, Oropharynx, Oral Cavity, Supraglottis or Larynx
AMG 319 in HPV Positive and Negative HNSCC
The purpose of this study is to determine whether a drug called AMG 319 has an effect on a patient's own immune response to head and neck cancer squamous cell carcinoma (HNSCC).
- Trial name
- NCT02540928
- Testing
- AMG 319 hydrate
- Where
- 5 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Cancer Research UK
HNSCC,Larynx, Pharynx and Oral Cavity
DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole
P16 negative cancers continue to have a dismal prognosis despite advances in the treatment of head and neck cancer. Acceleration, dose-escalation, hyperfractionation, chemotherapy and nimorazole has been shown to improve local…
- Trial name
- NCT01733823
- Testing
- 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
- Where
- 4 sites in Denmark
- Volunteers
- 31 people
- Sponsor
- Danish Head and Neck Cancer Group
Primary Non-operated Squamous Cell Carcinoma of Oral Cavity, Primary Non-operated Squamous Cell Carcinoma of Oropharynx
Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck
Severe acute and late dysphagia is now considered as a dose-limiting toxicity of radio(chemo)therapy for head and neck cancer that significantly affects patients' quality of life.
- Conditions
- Primary Non-operated Squamous Cell Carcinoma of Oral Cavity, Primary Non-operated Squamous Cell Carcinoma of Oropharynx, Primary Non-operated Squamous Cell Carcinoma of Hypopharynx, Primary Non-operated Squamous Cell Carcinoma of Larynx
- Trial name
- NCT01287390
- Testing
- video fluoroscopy, extra imaging, scoring acute toxicity
- Where
- 2 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- University Hospital, Ghent
Squamous Cell Carcinoma of the Oral Cavity, Oropharynx
Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium
The purpose of this research study is to collect information on whether images made using investigational microscopes can improve researchers' ability to evaluate and distinguish between normal and abnormal areas in tissue…
- Conditions
- Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Larynx, Hypopharynx
- Trial name
- NCT01321892
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Phase II Trial of Allovectin-7® for Head and Neck Cancer
The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors.
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of the Oral Cavity or Oropharynx, Head and Neck Neoplasms, Carcinoma of the Head and Neck
- Trial name
- NCT00050388
- Testing
- Allovectin-7®
- Where
- 10 sites in United States
- Sponsor
- Vical